GuideEndocrinology and nutrition
Pharmacotherapy for type 2 diabetes (Diabetes Canada)
Summary of the Diabetes Canada algorithm for choosing and adding glucose-lowering drugs in adults with type 2 diabetes.
Updated 3 November 2026
When to use it
Adults with type 2 diabetes at diagnosis, when not at HbA1c target, or after a cardiovascular event, heart failure or CKD diagnosis.
Warning
The 2020 update on which the original tool was based has been superseded by the Diabetes Canada 2024 update (October 2024).
Current version
The 2020 update (Lipscombe et al.) was superseded by the 2024 update of the type 2 diabetes pharmacotherapy chapter (Shah et al., Can J Diabetes, October 2024), with a companion user's guide. This sheet summarises the 2024 version and notes what is inherited from earlier versions.
Keep reading in the app
- First line
- Cardiorenal protection
- Intensification and drug choice
- Limitations
Practical tip
Cardiorenal benefit from SGLT2 inhibitors and GLP-1 RAs is pursued even when HbA1c is at target.
2 more practical tips in the app.
Reference
- Diabetes Canada Clinical Practice Guidelines Expert Working Group; Shah BR, Bajaj HS, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults—2024 update. Can J Diabetes. 2024;48(7):415-424.
- Diabetes Canada Clinical Practice Guidelines Expert Committee; Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020;44(7):575-591.
Official source: Diabetes Canada clinical practice guidelines
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
